The 2025 edition of the Drug Delivery to the Lungs (DDL) meeting is once again expected to draw approximately 1,100 inhaled and nasal drug delivery experts to the Edinburgh International Conference Centre (EICC). The conference, which will take place on December 10-12, features a lecture program, technology and poster exhibitions, along with numerous networking opportunities.
The DDL 2025 scientific program will begin the afternoon of December 10 with the presentation of the DDL Annual Lecture by Gerhard Scheuch, CEO of GS-Bio-Inhalation. Although no title has yet been announced for the talk, DDL organizing committee member Will Ganley says that Scheuch is expected to discuss his work on virus transmission as well as his experience in the development of OINDPs.
The program also includes the usual sessions for the DDL Emerging Scientist Award and the Pat Burnell Young Investigator Award, plus three lecture sessions titled, “Advances In Preclinical Drug Development,” “Making Innovation Happen,” and “To the Airways and Beyond.”
Ganley explains that the “Making Innovation Happen” session will address topics that go beyond the conference’s historical academic focus, including “entrepreneurship and the way that products get from academic science to through to real companies and real products that have a real impact on the world.”
The innovation session will include a plenary talk by David Morton of Deakin University titled “From Ideas to Products in Aerosol Drug Delivery (ADD): Barriers to Innovation,” in which Morton will present an overview of challenges to advancing OINDP products from academic science through to the market. Morton’s lecture will be followed by a panel discussion featuring several entrepreneurs in the OINDP space who will talk about their experiences in university spin-outs and start-ups.
